You are here

  • Home
  • Archive
  • Volume 8, Issue 6
  • Review: new generation antipsychotics do not induce fewer extrapyramidal side effects than low potency antipsychotics

Article Text

Article menu
Download PDFPDF
Therapeutics
Review: new generation antipsychotics do not induce fewer extrapyramidal side effects than low potency antipsychotics

https://doi.org/10.1136/ebm.8.6.175

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    (2003) Lancet 361, 1581. Leucht S, Wahlbeck K, Hamann J, et al.. New generation antipsychotics versus low-potency conventional antipsychotics: a systematic review and meta-analysis.. ;. :. –9.
    OpenUrlCrossRefPubMedWeb of Science

    
 
 QUESTION: In patients with schizophrenia, do new generation antipsychotics (NGAs) cause fewer extrapyramidal side effects (EPSs) than low potency antipsychotics (LPAs)?

    Data sources

    Studies were identified by searching the Cochrane Schizophrenia Group’s register of randomised trials (up to March 2002) and hand searching relevant journals and conference preceedings. Bibliographies of relevant articles were reviewed and manufacturers of new generation antipsychotics and authors of primary research articles were contacted for further studies and data verification.

    Study selection

    Studies were selected if they were randomised controlled trials (RCTs) that compared NGAs (eg, clozapine) with LPAs (eg, chlorpromazine) in patients with schizophrenia or other disorders with psychotic features.

    Data extraction

    2 reviewers independently extracted data on sample size, patient characteristics, details of the intervention, study duration and quality, and outcomes. The primary outcome was the number of patients who had ≥1 EPS. The major secondary outcome was the number of patients who achieved a clinically important …

    View Full Text

    Footnotes

    • Source of funding: no external funding.

    • For correspondence: Dr S Leucht, Universität München, Klinikum rechts der Isar, München, Germany. stefan.leucht{at}lrz.tum.de